A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Latest Information Update: 27 Sep 2024
At a glance
- Drugs Talazoparib (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2022 Planned End Date changed from 30 Jun 2022 to 22 Jul 2022.
- 07 Jun 2022 Planned End Date changed from 30 Nov 2022 to 30 Jun 2022.